secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023349
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology granted European patent covering ateganosine-based telomere-targeting anticancer therapy
--------------------------------------------------------------------------------

- European Patent Office grants patent for ateganosine-based analogues for telomere-targeting anticancer therapy.
- Patent titled 'Mercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere'; invented by CSO Sergei Gryaznov and SAB member Jerry Shay.
- MAIA's global IP portfolio now includes 10 issued patents worldwide, validated in 19 European countries, and 24 pending applications.
- Next-generation telomere-targeting agents aim to improve specificity toward cancer cells and increase anticancer activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225023349/0001641172-25-023349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225023349/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer